{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:03:32Z","timestamp":1756425812707,"version":"3.44.0"},"reference-count":25,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,2,23]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Multiple myeloma (MM) involving the breast tissue is rare. We report the case of a 70-year-old woman with a background of previously treated MM in remission presenting with a breast lump. Histology showed a plasma cell neoplasm and subsequent staging investigations showed widespread extramedullary relapse of MM. Despite its rarity, this diagnosis should be considered within the differential diagnosis of breast masses as it can arise de novo or may be the first presenting feature of myeloma. The importance of the multidisciplinary team approach with triple assessment of the breast, as well as recent advances in knowledge regarding extramedullary disease in myeloma and novel treatment approaches in MM are discussed.<\/jats:p>","DOI":"10.1136\/bcr-2020-239504","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T10:52:37Z","timestamp":1615287157000},"page":"e239504","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Extramedullary relapse of multiple myeloma presenting as a breast lump"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7262-7935","authenticated-orcid":false,"given":"Dale","family":"Seviar","sequence":"first","affiliation":[{"name":"Haematology Department, Eastbourne District General Hospital, East Sussex, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"AlshiekhAli","sequence":"additional","affiliation":[{"name":"Pathology Department, Eastbourne District General Hospital, Eastbourne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Howlett","sequence":"additional","affiliation":[{"name":"Radiology, Eastbourne District General Hospital, Eastbourne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"2025082802172099000_14.3.e239504.1","doi-asserted-by":"crossref","unstructured":"Kilciksiz S , Karakoyun-Celik O , Agaoglu FY . A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J 2012.","DOI":"10.1100\/2012\/895765"},{"key":"2025082802172099000_14.3.e239504.2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.078519"},{"key":"2025082802172099000_14.3.e239504.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-635383"},{"key":"2025082802172099000_14.3.e239504.4","unstructured":"Dos Anjos Corvo MA , Granato L , Ikeda F . Extramedullary nasal plasmacytoma: literature review and a rare case report. Int Arch Otorhinolaryngol Published Online First 2013."},{"key":"2025082802172099000_14.3.e239504.5","doi-asserted-by":"crossref","unstructured":"Urano M , Denewar FA , Okabe R . Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: imaging findings. Radiol Case Reports Published Online First 2019.","DOI":"10.1016\/j.radcr.2019.02.018"},{"key":"2025082802172099000_14.3.e239504.6","article-title":"Multiple myeloma breast involvement: a case report","volume":"2019","author":"Ali","year":"2019","journal-title":"Case Rep Radiol"},{"key":"2025082802172099000_14.3.e239504.7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402"},{"key":"2025082802172099000_14.3.e239504.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0196-8"},{"key":"2025082802172099000_14.3.e239504.9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.14827","article-title":"Guidelines for the use of imaging in the management of patients with myeloma","volume":"178","author":"Chantry","year":"2017","journal-title":"Br J Haematol"},{"key":"2025082802172099000_14.3.e239504.10","unstructured":"Binesh F , Vahedian HA , Shabani M . Extramedullary plasmacytoma of the breast: a case report and literature review. Acta Med. Iran 2018."},{"key":"2025082802172099000_14.3.e239504.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08157.x"},{"key":"2025082802172099000_14.3.e239504.12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698"},{"key":"2025082802172099000_14.3.e239504.13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman","year":"2018","journal-title":"Am J Hematol"},{"key":"2025082802172099000_14.3.e239504.14","unstructured":"Rosi\u00f1ol L , Cibeira MT , Uriburu C . Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006."},{"key":"2025082802172099000_14.3.e239504.15","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-019-03655-5","article-title":"Single-Agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study","volume":"98","author":"Jullien","year":"2019","journal-title":"Ann Hematol"},{"key":"2025082802172099000_14.3.e239504.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"2025082802172099000_14.3.e239504.17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the Griffin trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"2025082802172099000_14.3.e239504.18","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA , Lonial S , White D . Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 2017.","DOI":"10.1111\/bjh.14787"},{"key":"2025082802172099000_14.3.e239504.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"2025082802172099000_14.3.e239504.20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"2025082802172099000_14.3.e239504.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"2025082802172099000_14.3.e239504.22","doi-asserted-by":"crossref","unstructured":"Jagannath S , Lin Y , Goldschmidt H . A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa. J Clin Oncol 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.8525"},{"key":"2025082802172099000_14.3.e239504.23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: a phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R Mm)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"2025082802172099000_14.3.e239504.24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","article-title":"Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the cart before the horse","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025082802172099000_14.3.e239504.25","doi-asserted-by":"crossref","unstructured":"Topp MS , Duell J , Zugmaier G . Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (bite) immunotherapy, in R\/R multiple myeloma (Mm) patients: updated results of a first-in-human (FIH) phase I dose escalation study. J Clin Oncol 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.8007"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-239504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:17:30Z","timestamp":1756372650000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-239504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,9]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/bcr-2020-239504"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-239504","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}